As a secondary outcome , at 24 hours , more patients in the bupivacaine group were headache free ( 24.7 % difference ; 95 % CI 2.6 % to 43.6 % ) and more were nausea free ( 16.9 % difference ; 95 % CI 0.8 % to 32.5 % ) .